LIVE WEBINAR: Wednesday, May 18, 2022, 5:00 PM – 6:00 PM Eastern Time

What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial Participation

A 2-Part Complimentary NCPD Webinar Series

Gastroesophageal Cancers

Join us on Wednesday, May 18th for this NCPD-accredited webinar
5:00 PM – 6:00 PM ET

Faculty
Kristen K Ciombor, MD, MSCI
Associate Professor of Medicine
Division of Hematology/Oncology
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Jessica Mitchell, APRN, CNP, MPH
Assistant Professor of Oncology
Mayo Clinic College of Medicine and Science
Rochester, Minnesota

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from Astellas and Lilly.

Wednesday, May 18, 2022
5:00 PM – 6:00 PM Eastern Time
Live NCPD-accredited webinar

Topics to Be Discussed

MODULE 1: What I Tell My Patients About First-Line Therapy for Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Cancer

MODULE 2: What I Tell My Patients About the Tolerability of Immune Checkpoint Inhibitors in Combination with Chemotherapy

MODULE 3: What I Tell My Patients About First-Line Therapy for Metastatic HER2-Positive Gastric or GEJ Cancer

MODULE 4: What I Tell My Patients About the Selection and Sequencing of Therapy for Relapsed/Refractory (R/R) HER2-Negative Gastric and GEJ Cancer

MODULE 5: What I Tell My Patients About the Tolerability of Ramucirumab and TAS-102

MODULE 6: What I Tell My Patients About the Selection and Sequencing of Therapy for R/R HER2-Positive Gastric Cancer

MODULE 7: What I Tell My Patients About the Incidence and Management of Toxicities with T-DXd (Trastuzumab Deruxtecan)

MODULE 8: What I Tell My Patients About the Management of Metastatic Esophageal Cancer

MODULE 9: What I Tell My Patients About Adjuvant Anti-PD-1 Antibody Therapy for Esophageal Cancer

MODULE 10: What I Tell My Patients About Promising Investigational Strategies for Gastroesophageal Cancers

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of gastroesophageal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Educate patients about how HER2 status, PD-L1 combined positive score and other biologic and clinical factors influence personalized therapeutic recommendations for newly diagnosed locally advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer.
  • Describe the published research data with immune checkpoint inhibitors alone or in combination with chemotherapy in the management of gastric, GEJ and esophageal cancer, and review how these strategies fit into current nonresearch treatment algorithms.
  • Discern how available therapeutic agents and regimens can be applied in the care of patients with HER2-negative metastatic gastric, GEJ and esophageal cancer who have experienced disease progression on front-line chemotherapy or chemoimmunotherapy.
  • Appraise clinical trial findings supporting the use of adjuvant anti-PD-1 antibody therapy for patients with resected esophageal or GEJ cancer who have residual pathologic disease after neoadjuvant chemoradiation therapy, and discuss the clinical applicability of this strategy with appropriate individuals.
  • Recall available data with novel HER2-targeted agents and strategies for newly diagnosed and previously treated HER2-overexpressing gastric or GEJ cancer, and counsel patients who may be appropriate for these approaches about the risks and expected benefits.
  • Recognize common and rare side effects associated with approved and investigational agents used in the care of patients with gastroesophageal cancers, and apply this information to develop appropriate and effective supportive management plans.
  • Review the rationale for, available data with and ongoing research evaluating novel agents and strategies for gastroesophageal cancers, and effectively prioritize clinical trial opportunities for eligible patients.

Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NCPD Designation Statements
This educational activity for 1 contact hour is provided by RTP.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
https://www.researchtopractice.com/Meetings/ONS2022Gastro/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs Mitchell has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr CiomborAdvisory Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Personalis Inc, Pfizer Inc, Replimune; Consulting Agreements: Merck, Pfizer Inc, Seagen Inc; Contracted Research: Bristol-Myers Squibb Company, Calithera Biosciences, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Incyte Corporation, Merck, NuCana, Pfizer Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME and NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Astellas and Lilly.